The Food and Drug Administration (FDA) approved Zepbound in December 2024 for treating obstructive sleep apnea (OSA). Medicare Part D may cover Zepbound, but only when a doctor prescribes it for OSA.
Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.
The FDA approved a new drug called Zepbound, which activates GLP-1 to help with obstructive sleep apnea, while also resulting ...
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Terence Flynn, Morgan Stanley, inquired about Zepbound payer dynamics and access. Patrik Jonsson explained that Medicare coverage related to obstructive sleep apnea (OSA) is anticipated in the ...
Novo Nordisk’s Wegovy and Lilly’s Zepbound ... reduction, sleep apnea or metabolic dysfunction-associated steatohepatitis (MASH) among others to ensure insurance coverage under Medicare ...
The drugmaker could also explain how it plans to promote Zepbound to older Americans covered by Medicare ... cover the drug as a treatment for sleep apnea, they said. Zepbound is expected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results